CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

194 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
Clear
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
BTP53MutationPrognosticSupportsPoor OutcomeChronic Lymphocytic LeukemiaZenz et al., 2010
BTP53MutationPrognosticSupportsPoor OutcomeChronic Lymphocytic LeukemiaBaliakas et al., 2015
ATP53MutationPrognosticSupportsPoor OutcomeChronic Lymphocytic LeukemiaNadeu et al., 2016
BTP53MutationPrognosticSupportsLung Non-small Cell CarcinomaShepherd et al., 2017
BTP53MutationPrognosticSupportsPoor OutcomeMedulloblastoma SHH ActivatedSchwalbe et al., 2017
DTP53P250LFunctionalSupportsGain of FunctionXu et al., 2011
BTP53MutationPrognosticSupportsPoor OutcomeEsophagus Squamous Cell CarcinomaYamasaki et al., 2010
BTP53MutationPrognosticSupportsPoor OutcomeB-lymphoblastic Leukemia/lymphomaKrentz et al., 2013
BTP53MutationPrognosticSupportsPoor OutcomeMyelodysplastic SyndromeBally et al., 2014
BTP53MutationPrognosticSupportsPoor OutcomeMyeloid NeoplasmChng et al., 2007
BTP53MutationPrognosticDoes Not SupportPoor OutcomeHead And Neck Squamous Cell CarcinomaAlsner et al., 2001
BTP53MutationPrognosticSupportsPoor OutcomeHead And Neck Squamous Cell CarcinomaAlsner et al., 2001
BTP53Truncating MutationPrognosticSupportsPoor OutcomeHead And Neck Squamous Cell CarcinomaLindenbergh-van der Plas et al., 2011
BTP53Truncating MutationPrognosticDoes Not SupportPoor OutcomeHead And Neck Squamous Cell CarcinomaLindenbergh-van der Plas et al., 2011
BTP53MutationPrognosticSupportsPoor OutcomeB-lymphoblastic Leukemia/lymphomaHof et al., 2011
BTP53DNA Binding Domain MutationPrognosticSupportsPoor OutcomeOral Squamous Cell CarcinomaYamazaki et al., 2003
DTP53MutationPredictiveSupportsSensitivity/ResponseBreast CancerDoxorubicinJackson et al., 2012
BTP53MutationPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaMiddeke et al., 2016
BTP53Deleterious MutationPrognosticDoes Not SupportPoor OutcomeLung Non-small Cell CarcinomaMa et al., 2016
BTP53R72PPredisposingDoes Not SupportPredispositionBreast CancerSchmidt et al., 2007
BTP53MutationPrognosticSupportsPoor OutcomeChronic Lymphocytic LeukemiaZenz et al., 2008
BTP53ALTERATIONPredictiveSupportsResistanceOvarian CancerCarboplatin,CisplatinReles et al., 2001
BTP53OverexpressionPredictiveSupportsSensitivity/ResponseStomach CancerCisplatin,Etoposide,MitomycinBataille et al., 2003
DTP53WildtypePredictiveSupportsSensitivity/ResponseCancerRebemadlinEfeyan et al., 2007
DTP53WildtypePredictiveSupportsSensitivity/ResponseCancerMDM2 Inhibitor AMGMDS3Saiki et al., 2015
DTP53Deleterious MutationPredictiveSupportsResistanceCancerMDM2 Inhibitor AMGMDS3Saiki et al., 2015
DTP53Deleterious MutationPredictiveSupportsResistanceCancerRebemadlinEfeyan et al., 2007
BTP53ALTERATIONPrognosticSupportsPoor OutcomeOvarian CancerReles et al., 2001
DTP53R248QPredictiveSupportsResistanceCancerMDM2 Inhibitor AMGMDS3Saiki et al., 2015
DTP53R248WPredictiveSupportsResistanceCancerMDM2 Inhibitor AMGMDS3Saiki et al., 2015
DTP53R273CPredictiveSupportsResistanceCancerMDM2 Inhibitor AMGMDS3Saiki et al., 2015
DTP53R273HPredictiveSupportsResistanceCancerMDM2 Inhibitor AMGMDS3Saiki et al., 2015
DTP53G245SPredictiveSupportsResistanceCancerMDM2 Inhibitor AMGMDS3Saiki et al., 2015
DTP53Y220CPredictiveSupportsResistanceCancerMDM2 Inhibitor AMGMDS3Saiki et al., 2015
DTP53V157FPredictiveSupportsResistanceCancerMDM2 Inhibitor AMGMDS3Saiki et al., 2015
DTP53R249SPredictiveSupportsResistanceCancerMDM2 Inhibitor AMGMDS3Saiki et al., 2015
DTP53R280KPredictiveSupportsResistanceCancerMDM2 Inhibitor AMGMDS3Saiki et al., 2015
DTP53R280TPredictiveSupportsResistanceCancerMDM2 Inhibitor AMGMDS3Saiki et al., 2015
DTP53R158LPredictiveSupportsResistanceLung AdenocarcinomaMDM2 Inhibitor AMGMDS3Saiki et al., 2015
DTP53R248QPredisposingSupportsPredispositionLymphomaHanel et al., 2013
DTP53R248QFunctionalSupportsDominant NegativeBoettcher et al., 2019
DTP53Y220CFunctionalDoes Not SupportNeomorphicBoettcher et al., 2019
DTP53M237IFunctionalDoes Not SupportNeomorphicBoettcher et al., 2019
DTP53R248QFunctionalDoes Not SupportNeomorphicBoettcher et al., 2019
DTP53R273HFunctionalDoes Not SupportNeomorphicBoettcher et al., 2019
BTP53ALTERATIONPrognosticSupportsPoor OutcomeRhabdomyosarcomaShern et al., 2021
DTP53T125TFunctionalSupportsLoss of FunctionSaiki et al., 2015
BTP53MutationPredictiveSupportsSensitivity/ResponseMyelodysplastic SyndromeAzacitidine,EprenetapoptSallman et al., 2021
DTP53R175HPredictiveSupportsSensitivity/ResponseBreast CancerDoxorubicinJackson et al., 2012
BTP53R175HPrognosticSupportsPoor OutcomeBreast CancerOlivier et al., 2006
Page 1 of 4
Next